Icatibant: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Icatibant. Educational only — not medical advice.
Labeled uses
SAJAZIR (icatibant) injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.
Source: FDA labeling via NIH DailyMed (set 1756aca0…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.